'Clinical-grade' skincare online: what that label actually means

What just happened

Lauren Cortis, Senior Lecturer in Pharmacy Practice at the University of Adelaide, published a piece in The Conversation this week that addresses something appearing in increasing numbers of GP and dermatology consultations: patients buying prescription-strength skincare products online, sometimes having reactions, and not understanding what they bought or why it reacted.

The central point is precise: “clinical-grade” is a marketing term with no legal definition in Australia. It describes the packaging, not the regulation. A product labelled “clinical-strength” or “clinical-grade” has not been assessed for safety or efficacy under that claim. It may contain a prescription-level active. It may not. It may contain an active at a concentration that requires a prescription in Australia. There is no way to know from the label alone.

The three products Cortis specifically examines are tretinoin, hydroquinone, and topical corticosteroids — and each has a specific risk profile that matters for patients using them without medical oversight.

---

Both-and

Tretinoin: genuinely effective, genuinely risky without supervision

Tretinoin is a retinoid — a vitamin A derivative — with a well-established evidence base for acne, and a secondary evidence base for photoageing. It has gone viral on social media as a skincare active, and patients are accessing it through overseas online pharmacies and grey-market domestic suppliers.

The appeal is understandable: the evidence is real, the effect is visible, and it is dramatically cheaper to buy a tube online than to see a dermatologist or GP to get a prescription.

The risks of unsupervised use are also real. Tretinoin significantly increases photosensitivity — patients who are not counselled about this end up with sun damage that exceeds the damage they were trying to treat. It causes an initial irritation phase (“retinoid reaction”) that most patients interpret as an allergic reaction and abandon treatment, or mismanage by over-applying. And critically: tretinoin is contraindicated in pregnancy. A woman who buys it online, does not know she is pregnant, and continues use is exposed to a teratogen. That is not a theoretical risk — it is the kind of scenario that reaches general practice.

The supervision that comes with a prescription isn’t bureaucratic gatekeeping. It is a clinical encounter where contraindications are checked, the initial protocol is calibrated to skin type, and the photosensitivity counselling happens before the product is used, not after the burn.

Hydroquinone: the concentration threshold matters

Hydroquinone is used for hyperpigmentation — melasma, post-inflammatory pigmentation, sun spots. It is one of the most studied topical depigmentation agents.

In Australia, hydroquinone at concentrations up to 2% is available over the counter. Concentrations above 2% require a prescription. Products sold online as “clinical-grade” for pigmentation frequently contain higher concentrations — sometimes unlabelled.

The risk of prolonged high-dose use is exogenous ochronosis: a paradoxical, permanent darkening of the skin that is the opposite of the intended effect and is difficult or impossible to reverse. It is more common in darker skin types, and in patients who use higher-concentration products for extended periods without the monitoring a prescriber would provide.

There is also ongoing regulatory discussion internationally about carcinogenicity at higher concentrations with prolonged use. The Australian 2% OTC limit reflects this precautionary framing.

Topical corticosteroids: the hidden ingredient

Perhaps the most concerning story in this space is the one patients do not know about: topical corticosteroids appearing as undisclosed ingredients in skin-lightening products imported and sold online.

These products are sometimes marketed as “brightening creams” or “whitening creams” with no steroid disclosed on the label. Patients use them long-term because they see results — they do see results, because topical corticosteroids reduce inflammation and alter pigmentation. But extended unsupervised use of potent topical corticosteroids leads to skin atrophy, telangiectasia, and — with widespread or high-frequency application — systemic absorption sufficient to cause adrenal insufficiency.

Adrenal insufficiency from topical corticosteroids is a real adverse event documented in the literature and in the TGA’s adverse events database. It is preventable when a prescriber is involved. It is not preventable when a patient is buying a product online that does not disclose the ingredient.

The ARTG check is a usable tool

The Australian Register of Therapeutic Goods is publicly searchable — this is not insider knowledge. Any product making a therapeutic claim (treats acne, reduces pigmentation, reverses ageing damage) should be listed. If it isn’t, the claim has not been substantiated by the TGA’s regulatory process.

This is worth sharing with patients who are buying skincare online: before purchasing anything marketed with therapeutic-level language, check the ARTG. Products that are purely cosmetic — moisturisers making appearance claims without medical-level promises — do not require listing. But products claiming to treat a condition do.

---

My two cents

The patient who arrives with a reaction from a tretinoin product bought online is not doing something foolish. She read about it, she made a decision, she was trying to do something good for her skin with a product that has a genuine evidence base. The problem is not the product; it is the system that is set up to get her to the product without getting her to the clinician who would have calibrated it correctly for her.

General practice is the natural landing point for these conversations — not to lecture about self-prescribing, but to fill the gap between the product and the protocol. The “clinical-grade” label is doing real work on social media. The patient who has already been through a bad reaction is often more ready to hear what supervision would have changed than before she bought the product.

The ARTG check is a practical tool worth mentioning. The photosensitivity conversation for tretinoin is worth having early. And for any patient using a skin-lightening cream from an online supplier: it is worth asking what is actually in it.

Verdict: yes — “clinical-grade” is a marketing term, not a regulatory one, and the three actives most commonly sold under that label carry real, specific risks when used without clinical assessment. Worth raising in any consultation where patients mention skincare products bought online.

---

Sources cited

1. Cortis L. 3 clinical-grade skincare creams you really shouldn’t buy online. The Conversation, 30 July 2026. https://theconversation.com/3-clinical-grade-skincare-creams-you-really-shouldnt-buy-online-287770
2. Australian Register of Therapeutic Goods (ARTG). Therapeutic Goods Administration. https://www.tga.gov.au/products/australian-register-therapeutic-goods